Obagi Medical Partners with DermFx for Real-World Evidence Program on saypha® MagIQ™
Event summary
- Obagi Medical, part of Waldencast plc, has partnered with DermFx for the ALOHA Program to gather real-world evidence on Obagi® saypha® MagIQ™.
- DermFx will evaluate the product across multiple locations in Southern California, focusing on patient outcomes and practice integration.
- The program aims to translate clinical trial data into practical, everyday use in med spa settings.
- Initial findings will be presented at internal team meetings and regional events.
The big picture
This collaboration underscores a growing trend in the aesthetic medicine sector, where real-world evidence is becoming crucial for product adoption. By focusing on regional practices like DermFx, Obagi Medical aims to strengthen its position against larger national groups, emphasizing accessible, high-impact evaluation and protocols. The partnership also highlights Waldencast’s strategy of leveraging its portfolio brands to drive innovation in the beauty and wellness space.
What we're watching
- Program Effectiveness
- How the ALOHA Program will impact patient satisfaction and provider adoption of Obagi® saypha® MagIQ™ in real-world settings.
- Regional Expansion
- Whether DermFx’s success with the program could lead to similar partnerships with other regional med spa leaders.
- Competitive Positioning
- The pace at which Obagi Medical can differentiate itself in the injectable aesthetics market through evidence-based protocols.
Related topics